Literature DB >> 18519641

Akt-dependent regulation of NF-{kappa}B is controlled by mTOR and Raptor in association with IKK.

Han C Dan1, Matthew J Cooper, Patricia C Cogswell, Joseph A Duncan, Jenny P-Y Ting, Albert S Baldwin.   

Abstract

While NF-kappaB is considered to play key roles in the development and progression of many cancers, the mechanisms whereby this transcription factor is activated in cancer are poorly understood. A key oncoprotein in a variety of cancers is the serine-threonine kinase Akt, which can be activated by mutations in PI3K, by loss of expression/activity of PTEN, or through signaling induced by growth factors and their receptors. A key effector of Akt-induced signaling is the regulatory protein mTOR (mammalian target of rapamycin). We show here that mTOR downstream from Akt controls NF-kappaB activity in PTEN-null/inactive prostate cancer cells via interaction with and stimulation of IKK. The mTOR-associated protein Raptor is required for the ability of Akt to induce NF-kappaB activity. Correspondingly, the mTOR inhibitor rapamycin is shown to suppress IKK activity in PTEN-deficient prostate cancer cells through a mechanism that may involve dissociation of Raptor from mTOR. The results provide insight into the effects of Akt/mTOR-dependent signaling on gene expression and into the therapeutic action of rapamycin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18519641      PMCID: PMC2418585          DOI: 10.1101/gad.1662308

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  48 in total

Review 1.  The IKK complex: an integrator of all signals that activate NF-kappaB?

Authors:  A Israël
Journal:  Trends Cell Biol       Date:  2000-04       Impact factor: 20.808

2.  Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B.

Authors:  Nywana Sizemore; Natalia Lerner; Nicole Dombrowski; Hiroaki Sakurai; George R Stark
Journal:  J Biol Chem       Date:  2001-12-03       Impact factor: 5.157

Review 3.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

4.  Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action.

Authors:  Kenta Hara; Yoshiko Maruki; Xiaomeng Long; Ken-ichi Yoshino; Noriko Oshiro; Sujuti Hidayat; Chiharu Tokunaga; Joseph Avruch; Kazuyoshi Yonezawa
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

5.  Akt deficiency impairs normal cell proliferation and suppresses oncogenesis in a p53-independent and mTORC1-dependent manner.

Authors:  Jennifer E Skeen; Prashanth T Bhaskar; Chia-Chen Chen; William S Chen; Xiao-ding Peng; Veronique Nogueira; Annett Hahn-Windgassen; Hiroaki Kiyokawa; Nissim Hay
Journal:  Cancer Cell       Date:  2006-10       Impact factor: 31.743

6.  Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38.

Authors:  L V Madrid; M W Mayo; J Y Reuther; A S Baldwin
Journal:  J Biol Chem       Date:  2001-03-20       Impact factor: 5.157

7.  An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice.

Authors:  K Podsypanina; R T Lee; C Politis; I Hennessy; A Crane; J Puc; M Neshat; H Wang; L Yang; J Gibbons; P Frost; V Dreisbach; J Blenis; Z Gaciong; P Fisher; C Sawyers; L Hedrick-Ellenson; R Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

8.  Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Authors:  M S Neshat; I K Mellinghoff; C Tran; B Stiles; G Thomas; R Petersen; P Frost; J J Gibbons; H Wu; C L Sawyers
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

9.  TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90.

Authors:  Guoqing Chen; Ping Cao; David V Goeddel
Journal:  Mol Cell       Date:  2002-02       Impact factor: 17.970

10.  mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery.

Authors:  Do-Hyung Kim; D D Sarbassov; Siraj M Ali; Jessie E King; Robert R Latek; Hediye Erdjument-Bromage; Paul Tempst; David M Sabatini
Journal:  Cell       Date:  2002-07-26       Impact factor: 41.582

View more
  241 in total

1.  Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance.

Authors:  Kazuhiro Tanaka; Ivan Babic; David Nathanson; David Akhavan; Deliang Guo; Beatrice Gini; Julie Dang; Shaojun Zhu; Huijun Yang; Jason De Jesus; Ali Nael Amzajerdi; Yinan Zhang; Christian C Dibble; Hancai Dan; Amanda Rinkenbaugh; William H Yong; Harry V Vinters; Joseph F Gera; Webster K Cavenee; Timothy F Cloughesy; Brendan D Manning; Albert S Baldwin; Paul S Mischel
Journal:  Cancer Discov       Date:  2011-09-13       Impact factor: 39.397

2.  mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.

Authors:  Vanessa S Rodrik-Outmezguine; Sarat Chandarlapaty; Nen C Pagano; Poulikos I Poulikakos; Maurizio Scaltriti; Elizabeth Moskatel; José Baselga; Sylvie Guichard; Neal Rosen
Journal:  Cancer Discov       Date:  2011-06-17       Impact factor: 39.397

3.  NF-κB in Aging and Disease.

Authors:  Jeremy S Tilstra; Cheryl L Clauson; Laura J Niedernhofer; Paul D Robbins
Journal:  Aging Dis       Date:  2011-12-02       Impact factor: 6.745

4.  NF-κB inhibition delays DNA damage-induced senescence and aging in mice.

Authors:  Jeremy S Tilstra; Andria R Robinson; Jin Wang; Siobhán Q Gregg; Cheryl L Clauson; Daniel P Reay; Luigi A Nasto; Claudette M St Croix; Arvydas Usas; Nam Vo; Johnny Huard; Paula R Clemens; Donna B Stolz; Denis C Guttridge; Simon C Watkins; George A Garinis; Yinsheng Wang; Laura J Niedernhofer; Paul D Robbins
Journal:  J Clin Invest       Date:  2012-06-18       Impact factor: 14.808

Review 5.  NF-κB addiction and its role in cancer: 'one size does not fit all'.

Authors:  M M Chaturvedi; B Sung; V R Yadav; R Kannappan; B B Aggarwal
Journal:  Oncogene       Date:  2010-12-20       Impact factor: 9.867

6.  NEK2 induces drug resistance mainly through activation of efflux drug pumps and is associated with poor prognosis in myeloma and other cancers.

Authors:  Wen Zhou; Ye Yang; Jiliang Xia; He Wang; Mohamed E Salama; Wei Xiong; Hongwei Xu; Shashirekha Shetty; Tiehua Chen; Zhaoyang Zeng; Lei Shi; Maurizio Zangari; Rodney Miles; David Bearss; Guido Tricot; Fenghuang Zhan
Journal:  Cancer Cell       Date:  2013-01-14       Impact factor: 31.743

7.  Inhibition of human immunodeficiency virus (HIV-1) infection in human peripheral blood leucocytes-SCID reconstituted mice by rapamycin.

Authors:  F Nicoletti; C Lapenta; C Lamenta; S Donati; M Spada; A Ranazzi; B Cacopardo; K Mangano; F Belardelli; C Perno; S Aquaro
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

8.  Protein kinase C-delta and phosphatidylinositol 3-kinase/Akt activate mammalian target of rapamycin to modulate NF-kappaB activation and intercellular adhesion molecule-1 (ICAM-1) expression in endothelial cells.

Authors:  Mohd Minhajuddin; Kaiser M Bijli; Fabeha Fazal; Antonella Sassano; Keiichi I Nakayama; Nissim Hay; Leonidas C Platanias; Arshad Rahman
Journal:  J Biol Chem       Date:  2008-12-13       Impact factor: 5.157

9.  Interferon regulatory factor 4 sustains CD8(+) T cell expansion and effector differentiation.

Authors:  Shuyu Yao; Bruno Fernando Buzo; Duy Pham; Li Jiang; Elizabeth J Taparowsky; Mark H Kaplan; Jie Sun
Journal:  Immunity       Date:  2013-11-07       Impact factor: 31.745

10.  mTOR signaling and transcriptional regulation in T lymphocytes.

Authors:  Hu Zeng; Hongbo Chi
Journal:  Transcription       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.